Former President Donald Trump’s return to the White House will bring changes to the healthcare sector, affecting reproductive care, insurance programs, and prescription drugs. Tariffs proposed by Trump could raise drug development costs and consumer prices, impacting pharmaceutical companies. Experts predict increased mergers and acquisitions in the pharmaceutical industry under the Trump administration. Changes to the Inflation Reduction Act are uncertain, as Republican lawmakers may repeal drug pricing revisions. There is potential for reform in pharmacy benefit managers and promising prospects for psychedelic research under the upcoming Trump administration. The future of prescription drugs is uncertain, dependent on Trump’s agency appointments and Congress priorities.
Source link
What Might the Future of Prescription Drugs Look Like Under Trump?
